Posterior Segment Eye Disorders Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Posterior Segment Eye Disorders Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The posterior segment eye disorders market was valued at USD 28,360.55 million in 2021, and it is expected to reach USD 37,454.56 million by 2027, registering a CAGR of 5.03% during the period, 2022-2027.

The COVID-19 pandemic disrupted the research and development activities of other therapies and drugs for medical conditions other than COVID-19 and impacted the treatment procedures and supply chains of pharmaceuticals and medical devices around the world, which also impacted the studied market for posterior segment eye disorders. For instance, according to a health article published in March 2021, titled "The Covid-19 pandemic accelerates the worsening of glaucoma cases", the impact of COVID-19 has caused very serious and irreversible consequences for people with glaucoma who have suffered a very rapid evolution of the disease and have not been able to carry out the follow-up by the specialist, which, in some cases, has resulted in a loss of the visual field. Therefore, the overall impact of COVID-19 on the posterior segment eye disorders market was adverse, primarily due to the decline in the diagnostics and treatment procedures of the diseases associated with the posterior segment of the eye, but with the ongoing vaccination programs and the launch of new drugs against COVID-19, the studied market is expected to bounce back to its full potential over the coming years.

The posterior segment eye disorders are one of the major causes of visual impairments around the world, and their prevalence is increasing gradually owing to the increase in the prevalence of eye diseases, diabetes, and geriatric populations that are more vulnerable to eye ailments. With the increase in the burden of these diseases, the demand for diagnostics and treatment is increasing around the world, which is driving the growth of the studied market for posterior segment eye disorders.

For instance, according to the research study published in September 2020, titled "Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers", posterior segment eye diseases can result in severe vision loss and affect more than 300 million people around the world, which shows a significant burden of the disorders around the world. Also, several other research studies showed that posterior eye disorders are associated with the loss of vision, which is why the demand for diagnostics and therapeutics is increasing in the studied area of the market. With the rising awareness of these diseases, the market for posterior segment eye disorders is expected to grow during the forecast period of the study.

Furthermore, with the launch of new products in the area by the key market players in the studied market along with other developments such as research and development collaboration and mergers and acquisitions, the studied market for posterior segment eye disorders is further expected to grow during the forecast period. For instance, in June 2020, Senju Pharmaceutical and OtsUnited Kingdoma Pharmaceuticals launched a new combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE Combination Ophthalmic Suspension, in Japan.

Moreover, due to the rising awareness about eye disorders along with the factors mentioned above, the posterior segment eye disorders market is expected to register healthy growth over the forecast period of the study. However, owing to factors such as stringent regulatory policies of different countries and the lack of proper healthcare infrastructure in the developing and under-developing countries, the market's growth is expected to be affected over the forecast period of the study.

Compounds with a low molecular weight that can change the biochemical processes for treating diseases are known as small-molecule drugs. Factors such as the growing burden of eye disorders, increasing research and development for the innovation of new therapeutics, and the launch of the products are driving the market segment's growth over the forecast period.

Several research studies depict the potential of small molecules for treating posterior segment eye diseases, propelling the market segment growth. For instance, the Pharmaceutics Journal article titled "Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutics and Pharmacokinetic Considerations" published in March 2020, reported that the posterior route is the main elimination pathway for small and lipophilic molecules since they can easily cross the retina. The diffusion process could occur via the paracellular and/or transcellular routes.

The market segment is also boosted by increasing clinical studies and collaboration among the market players. For instance, in January 2020, Ocuphire Pharma, Inc., entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian's Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. It is a first-in-class, orally-administered, small molecule drug candidate that selectively targets and inhibits the Ref-1 (reduction-oxidation effector factor-1)

Furthermore, in December 2021, AbbVie Inc. (Allergan) received approval for VUITY (pilocarpine HCl ophthalmic solution) 1.25% by United States Food and Drug Administration (FDA) to treat presbyopia and be available by prescription in pharmacies in United States. Such launches are expected to drive the growth of the market segment. Thus, the small molecules segment is expected to project growth over the forecast period owing to the aforementioned factors.

North America is anticipated to have significant market growth owing to its well-established healthcare infrastructure, the presence of key market players, new product launches, and the rising burden of posterior eye disorders in the region.

Diabetic retinopathy is one of the leading disorders of the posterior segment of the eye. For instance, according to the Government of Canada, Diabetes Canada report published in February 2020, diabetic retinopathy is one of the leading causes of vision loss in people of working age. It also reported that the prevalence of diabetic retinopathy is approximately 25.1% in Canada. Thus, such a high prevalence will increase the demand for treatment, thereby boosting the market's growth in the region.

Moreover, mergers and acquisitions are one of the key reasons for the growth of the market in the region. For instance, in November 2021, Alcon acquired Ivantis, Inc. to increase its product portfolio by adding the Hydrus microstent for surgical glaucoma. Hydrus microstent is one of the key products in Canada. With this acquisition, Alcon will increase its presence in the market.

Likewise, in September 2021, Zilia Inc. received USD 3.16 million through seed financing. This would aid the company's entry into ocular diagnostics by increasing the number of diagnoses for posterior segment eye disorders. The product can measure oxygen saturation in the eye, an important biomarker for eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration.

Hence, owing to the abovementioned factors, the studied market is expected to have faster growth over the forecast period.

The market for posterior segment eye disorders is moderately fragmented. Market players are focusing on new product launches, product innovation, regional expansions, and collaborations to increase their market share. The key market players operating in the market include F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., Rainbow Medical Ltd. (Nano Retina), Second Sight Medical, and Merck & Co., Inc., among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support